The global demand for medicines is rapidly increasing as people live longer, diagnostic methods improve, and the treatment of rare diseases evolve. Biologic drugs and cell therapies represent the next wave of therapeutics being developed to target diseases in a highly specific manner, making them much more efficient and safer than previous methods. However, the development of these types of therapies is time consuming, highly complex and far more expensive than their predecessors.
Valitacell is a biotechnology company that develops, markets and sells technology to biopharmaceutical, contract development and manufacturing companies, enabling them to make biological drugs and cell therapies faster, cheaper and with greater regulatory confidence. We are addressing key challenges across the Cell Line Development (CLD) and cell manufacturing sectors through a detailed understanding of how cells behave. Our innovative Quantum and ChemStress platform technologies enable much deeper characterisation of cells and their function, providing analytical solutions for robust process control of the biologic and cell manufacturing processes.
As we continue to develop the next generation of cell characterisation tools it is essential to consider their optimal integration into a variety of diverse manufacturing systems. Valitacell are working in collaboration with live cell imaging and automation partners in the CLD space to develop an integrated platform with transformative capabilities for the imaging and biomarker analysis of living cells. At the same time, we are extending the use of our platform technologies into the field of cell therapy and stem cell manufacturing, in collaboration with the Regenerative Medicine Institute (REMEDI), NUI Galway, Ireland. II-LCA has facilitated the recruitment and incorporation of an Innovation Associate with live cell imaging, life science instrumentation and automation expertise. The IA will support Valitacell in the development of novel integrated biologic and cell therapy manufacturing systems, enhancing our capabilities in this space, strengthen existing collaborations, and generate further opportunities for future innovation.
